Responses

Download PDFPDF

Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Inhaled corticosteroids and mortality in COPD

    Dear Editor,

    We read with interest the recent paper by Sin and colleagues (1) which, we believe, raises more questions that it answers.

    A major concern is the fact that ascertainment of mortality was incomplete for a significant proportion of patients (973/5086), corresponding to 19% of the total (not the reported 12%), who did withdraw prematurely from the study. This loss to follow up was more likely...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Inhaled corticosteroids and COPD mortality: are we there yet?

    Dear Editor,

    Inhaled corticosteroids have for some time been seeking a broader indication in COPD. The recent meta-analysis by Sin et al.[1] suggesting protection against all-cause mortality is therefore of some interest. Although not universally confirmed[2,3], this tantalising concept is being prospectively evaluated in a 3 year study of high dose inhaled corticosteroids (Flixotide 500mcg bid, alone or in combina...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Inhaled steroids Protect Heart in COPD Patients

    Dear Editor

    Chronic obstructive pulmonary disease and other disorders, associated with reduced lung function, are strong risk factors for cardiovascular events, independent of smoking. In general, for every 10% decrease in FEV1, all-cause mortality increases by 14%, cardiovascular mortality increases by 28%1. Patients with chronic obstructive pulmonary disease (COPD) are predisposed to atherosclerosis and coronary...

    Show More
    Conflict of Interest:
    None declared.